EMA to accept pCR as breast cancer endpoint

EMA issued (see BioCentury Extra, May 29, 2012).

EMA did state that pCR could support approval as add-on therapy in the neoadjuvant setting, but said approval would be conditional on confirmatory trials using disease-free or overall survival (OS). Comments on the EMA guidance are due July 31. ...